Search results
Moderna Stock Is Having Another Very Bad Day. Here’s Why.
Barrons.com· 6 days agoThe drop comes as Moderna awaits important developments involving its experimental cancer treatment,...
The U.S. Is Close To Bankrolling Moderna's Bird Flu Vaccine As Third Dairy Worker Tests Positive
Investor's Business Daily· 5 days agoModerna stock jumped 2.4%, closing at 151.49. Pfizer stock rose to 1.4% to 28.19. Moderna Stock:...
The new technology inside COVID-19 vaccines— mRNA
KRGV Rio Grande Valley· 2 days agoWhen you think of vaccines, you may think about traditional vaccines with weak or inactive parts of a virus to trigger an immune response. Today...
US nears deal to fund Moderna’s bird flu vaccine trial, FT reports
WHTC 1450 Holland· 5 days ago(Reuters) - The U.S. government is nearing an agreement to fund a late-stage trial of Moderna's mRNA...
FDA approves Moderna's mRNA RSV vaccine for older adults
News Channel Nebraska· 8 hours agoBy Jen Christensen, CNN
FDA approves Moderna’s mRNA RSV vaccine for older adults - ABC17NEWS
ABC17 NEWS· 4 days agoThe shot, made by Moderna and sold under the name of mResvia, could be another tool in the country’s RSV arsenal in the fall. Moderna’s shot is the third ...
Moderna Shares Had a Bad Day
Barrons.com· 7 days agoThe drop comes as Moderna awaits important developments involving its experimental cancer treatment, a new respiratory vaccine, and a possible avian flu...
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
Digital Journal· 4 days agomRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, ...
Moderna Looks for Boost From Newly Approved RSV Shot
The Wall Street Journal· 4 days agoThe U.S. Food and Drug Administration approved Moderna’s vaccine to protect against respiratory syncytial virus, or RSV, a common virus that is among the...
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says
Reuters· 1 day agoVaccine makers should consider targeting one of the currently dominant JN.1 variants and...